Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 10, 1999, Pages 2451-2456

  Preston, Sandra L ^a   Drusano, George L ^a   Glue, Paul ^b   Nash, Jacqueline ^a   Gupta, S K ^b   McNamara, P ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARBON 13; RIBAVIRIN; STABLE ISOTOPE;

ADULT; ARTICLE; BLOOD SAMPLING; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG URINE LEVEL; HEPATITIS C; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0032862514     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.10.2451     Document Type: Article

References (23)

1. Brillanti, S., J. Garson, M. Foli, K. Whitby, R. Deaville, C. Masci, M. Migliotti, and L. Barbara. 1994. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107:812-817.
2. Browne, T. R. 1990. Stable isotopes in clinical pharmacokinetic investigations: advantages and disadvantages. Clin. Pharmacokinet. 18:423-433.
3. 14C-ribavirin: distribution and pharmacokinetic studies in rats, baboons, and man, p. 83-98. In R. A. Smith and W. Kirkpatrick (ed.), Ribavirin: a broad spectrum antiviral agent. Academic Press, Inc., New York, N.Y.
4. Chemello, L., L. Cavalletto, E. Bernardinello, M. Guido, P. Pontisso, and A. Alberti. 1995. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J. Hepatol. 23(Suppl 2.):8-12.
5. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
6. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, Calif.
7. Davis, G. L., R. Esteban-Mur, V. Rustgi, J. Hoefs, S. Gordon, C. Trepo, M. Shiffman, S. Zeuzem, A. Craxi, C. Raffanel, R. Reindollar, M. Rizzetto, and the International Hepatitis Interventional Therapy Group. 1997. Retreatment of relapse after interferon therapy for chronic hepatitis C: an international randomized controlled trial of interferon plus ribavirin vs interferon alone. Hepatology 26:247A.
8. Falconnet, J. B., N. El Tayar, A. Bechalany, et al. 1989. Isotope effects on lipophilicity, synthesis, and applications of isotopically labelled compounds, p. 355-360. In T. A. Bailie and J. R. Jones (ed.), Synthesis and applications of isotopically labelled compounds 1988. Elsevier, New York, N.Y.
9. Glue, P. 1999. Ribavirin: clinical pharmacology and mechanism of action. Semin. Liver Dis. 19(Suppl. 1):17-24.
10. Hoofnagle, J. H., and A. M. DiBisceglie. 1997. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:347-356.
11. Khakoo, S., P. Glue, L. Grellier, B. Wells, A. Bell, C. Dash, I. Murray-Lyon, D. Lypnyj, B. Flannery, K. Walters, and G. M. Dusheiko. 1998. Ribavirin and interferon alpha-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br. J. Pharmacol. 46:563-570.
12. Lai, M. Y., P. M. Yang, J. H. Kao, J. T. Wang, H. S. Lee, and D. S. Chen. 1993. Combination therapy of α-interferon and ribavirin in patients with chronic hepatitis C: an interim report. Hepatology 18(Suppl.):93A (abstr.).
13. Laskin, O. L., J. A. Longstreth, C. C. Hart, D. Scavuzzo, C. M. Kalman, J. D. Connor, and R. B. Roberts. 1987. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin. Pharmacol. Ther. 41:546-555.
14. Lertora, J. J. L., A. B. Rege, J. T. Lacour, N. Ferencz, W. J. George, R. B. VanDyke, K. C. Agrawal, and N. E. Hyslop, Jr. 1991. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 50:442-449.
15. March, J. 1992. Advanced organic chemistry, p. 226. John Wiley & Sons, Inc., New York, N.Y.
16. Page, T., and J. D. Connor. 1990. The metabolism of ribavirin in erythrocytes and nucleated cells. Int. J. Biochem. 22:379-383.
17. Paroni, R., M. Del Puppo, C. Borghi, C. R. Sirtori, and M. G. Kienle. 1989. Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-tirazole-3-carboxamide in normal volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol. 27:302-307.
18. i) transporter. Pharm. Res. 15:950-952.
19. Reichard, O., G. Norkrans, A. Fryden, J. H. Braconier, A. Sonnerborg, and O. Weiland. 1998. Randomised, double-blind, placebo-controlled trail of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 351:83-87.
20. Schulman, N. R. 1984. Assessment of hematologic effects of ribavirin in humans, p. 79-92. In Clinical applications of ribavirin. Academic Press, Inc., New York, N.Y.
21. Simon, H., and D. Palm. 1966. Isotope effects in organic chemistry and biochemistry. Angew. Chem. Int. Ed. 5:921-933.
22. Wolen, R. L. 1986. The application of stable isotopes to studies of drug bioavailability and bioequivalence. J. Clin. Pharmacol. 26:419-424.
23. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.